Quantcast

Latest acute lymphoblastic leukemia Stories

2014-09-10 16:25:08

Stage set to determine if drugs called tyrosine kinase inhibitors will extend the lives of patients with the high-risk acute lymphoblastic leukemia subtype; pediatric clinical trial scheduled to open by early 2015 MEMPHIS, Tenn., Sept. 10, 2014 /PRNewswire-USNewswire/ -- More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of...

2014-09-03 04:21:54

AMSTERDAM, September 3, 2014 /PRNewswire/ -- ~ Clinical and Business Development expert re-joins the Company ~ Kiadis Pharma B.V. ("Kiadis Pharma", "Kiadis" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most recently Chief Medical Officer at Ceronco Biosciences. Prior...

2014-08-26 23:13:53

CEHN’s Childhood Leukemia Fact Sheet, which provides tips on how to reduce exposure to environmental risk factors associated with childhood leukemia, is now available in Spanish. Washington, DC (PRWEB) August 26, 2014 The Children’s Environmental Health Network’s (CEHN) Childhood Leukemia Fact Sheet, created with the University of California at Berkeley’s Center for Integrative Research on Childhood Leukemia and the Environment (CIRCLE), has been translated and is now available in...

2014-08-07 20:24:36

Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug. 7, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic...

2014-07-10 12:30:41

WINDSOR, England, July 10, 2014 /PRNewswire/ -- Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylatedL-asparaginase, Oncaspar(R) (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. (Logo: http://photos.prnewswire.com/prnh/20140710/696813 ) The submission is...

2014-07-07 12:29:12

- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014 /PRNewswire/ -- Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic...

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-17 13:07:52

Walter and Eliza Hall Institute of Medical Research Melbourne researchers have shown a type of leukaemia can be successfully ‘reversed’ by coaxing the cancer cells back into normal development. The discovery was made using a model of B-progenitor acute lymphoblastic leukaemia (B-ALL), the most common cancer affecting children. Researchers from the Walter and Eliza Hall Institute showed that switching off a gene called Pax5 could cause cancer in a model of B-ALL, while restoring...

2014-06-02 16:25:22

Nonadherence Triples Relapse Risk, More Prevalent in African American and Asian Children WASHINGTON, June 2, 2014 /PRNewswire-USNewswire/ -- An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online in Blood, the Journal of the American Society of Hematology (ASH). The study also reports that maintenance medication...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related